Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia

Haematologica

Volumn 100, Issue 5, 2015, Pages e196-e199

  Peterlin, Pierre ^a,b   Renneville, Aline ^c   Abdelali, Raouf Ben ^d   Nibourel, Olivier ^c   Thomas, Xavier ^e   Pautas, Cécile ^f   De Botton, Stéphane ^g   Raffoux, Emmanuel ^a,d   Cayuela, Jean Michel ^a,d   Boissel, Nicolas ^a,d   Terré, Christine ^h   Celli Lebras, Karine ^d   Castaigne, Sylvie ^h   Preudhomme, Claude ^c   Gardin, Claude ^a,i   Dombret, Hervé ^d  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h CENTRE HOSPITALIER DE VERSAILLES   (France)

ⁱ AVICENNE HOSPITAL   (France)

Author keywords

CN AML heterogeneity; Cytogenetically normal; NPM1 mutation

Indexed keywords

DNA FRAGMENT; NUCLEOPHOSMIN; NUCLEAR PROTEIN; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NUCLEOPHOSMIN 1 GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; GENETICS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MORTALITY; MUTATION; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84929148668     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.115576     Document Type: Article

References (15)

1. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254-266.
2. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115(3):453-474.
3. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14):2348-2355.
4. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636-3643.
5. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
6. Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012;26(6):1247-1254.
7. Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742-750.
8. Gaidzik VI, Schlenk RF, Paschka P, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013; 121(23):4769-4777.
9. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010;28(5):808-14.
10. Thomas X, Elhamri M, Raffoux E, et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood. 2011;118(7):1754-1762.
11. Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109(12):5129-3515.
12. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-1516.
13. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
14. Zhou KG, Jiang LJ, Shang Z, Wang J, Huang L, Zhou JF. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis. Leuk Lymphoma. 2012;53(12):2423-2429.
15. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111(7):2548-2553.